Photo Credit: alexgrec

The following is a summary of “Brodalumab is Effective for Psoriasis Patients with Difficult-to-treat Body Regions: Results from an Observational Clinical Study,” published in the November 2024 issue of Dermatology by Dauth et al. 

Researchers conducted a retrospective study to investigate the effectiveness of brodalumab for treating difficult-to-manage body regions in moderate-to-severe plaque psoriasis in clinical practice.  

They examined patients with nail and scalp psoriasis who received brodalumab during routine clinical care at 7 centers in Germany and observed participants for 60 weeks. The co-primary endpoints were a 75% improvement in the Psoriasis Scalp Severity Index (PSSI75) at week 12 and a 75% improvement in the Nail Psoriasis Severity Index (NAPSI75) at week 24, whereas secondary endpoints included evaluations of general skin and disease outcomes, QoL, and patient satisfaction with treatment.  

The results showed 87 patients were included, with a mean age of 46.8 years, 70.1% male, and a mean body mass index of 28.9 kg/m². Among the 62 patients who met the criteria for effectiveness analyses, over 90% achieved the co-primary endpoints: 93.6% achieved the PSSI75 at week 12, and 90.3% achieved the NAPSI75 at week 24. Median body surface area involvement decreased from 14% at baseline to 1.5% at week 12 and 1% at week 24. Median Dermatology Life Quality Index scores improved from 16 at baseline to 2 at week 12 and 1 at week 24. Improvements were sustained in most patients throughout the 60-week study. Brodalumab was well tolerated, and the patients reported high satisfaction with the treatment.  

They concluded that brodalumab demonstrated long-term clinical effectiveness in improving scalp and nail psoriasis in a real-world setting, supporting its use for difficult-to-treat body regions. 

Source: karger.com/drm/article/doi/10.1159/000542348/915613/Brodalumab-is-Effective-for-Psoriasis-Patients